Rentschler Biopharma SE’s new production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational. The new production line is the largest investment in Rentschler Biopharma’s more than 150-year history.

The CDMO already has a major project underway at the new line, with several additional projects in the pipeline, and continues to welcome new projects and clients.

The multi-product facility, which doubles Rentschler Biopharma’s global cGMP capacity, is focused mainly on commercial production of highly complex molecules. The original Milford site went from a single-product commercial facility to producing multiple products in an up to 500L bioreactor setup. The new production line has added 22,000 square feet of manufacturing cleanroom space and houses four new 2,000L single-use bioreactors, bringing the total of production lines at the site up to three.

Benedikt von Braunmühl, CEO of Rentschler Biopharma SE, commented: “The completion of our new, state-of-the-art production line is an important milestone for our company and emphasizes Rentschler Biopharma’s strong capabilities in the U.S. Our clients are our partners, and we are working with them to empower tomorrow’s therapies today.”

Rentschler Biopharma acquired the Milford site in 2019. Since then, the company has transformed the facility into a multi-product manufacturing site, expanding it from 93,000 square feet to 138,000 square feet in total. Earlier this year, the company received the Gold Award for the Central Massachusetts region in the 20th Annual Team Massachusetts Economic Impact Awards for its significant contributions to job growth, facility expansion, investment, and community engagement.